Member Info for Jiving

We are number 2 on LSE risers at present, so much better than being number 2 on the fallers:
https://www.lse.co.uk/share-prices/risers.html

14.5m traded. Pretty healthy volume. Is this FOMO pre ERS & will it continue?

We 'might' be in play in as soon as 3 weeks. My hope is the pharma's approach us with interest after ERS, before we need to start mailing data sets to them end 2H.

Indeed actually a few 1m+ buys near the full ask.

Useful stuff Mars. Also the company mentioned it themselves in their 28 July RNS:
"NXP002, as a potential treatment for IPF, is a likely candidate for Orphan Drug Designation which could provide additional product protection against potential competitors."

Again an issue worthy of a sentence or two's explanation by our management.

Actually given all the extreme price volatility we have seen for many commodities & significant interest rate & FX movements, I think it would be quite rational & legitimate for EPC/finance to be delayed into early autumn. If we have nothing first week Sept it wont bother me - unless there is an RNS saying its all off.

Really hope you are right on that one NFT, but which one - 002 or 004 - first?

It would really help if a member of our newly announced senior management spent 15 mins in an interview spelling out their view on the road ahead.

Lynparza seems to be something of a superdrug as far as various forms of cancer are concerned, & Merck buying into it later at a very high price confirms that. Again as per our anti fibrotic drug, we seem to be in the right place/right time with NXP004. Which LTH realise but seemingly nobody else on the planet does, hence our share price. In turn that means if/when we get a deal the % rise will be extraordinary.

No, all selling matters as far as the share price is concerned, regardless of its source. An excess of supply over demand drives the price down - that can come from a share sale agreement like Lanstead, from a major shareholder selling or from insider knowledge driven selling - whether that 'knowledge' is true or false.

At present we are at a delicate crossroads with sentiment recovering somewhat with the BOD appointments & good news on NXP002, but the turnover is still very low on an average day. So the monthly share sale when it occurs can have a serious % effect as it 'possibly' has done today, an extra 5.5m shares (some 0.8% of share capital) still has to be absorbed by extra demand.

8m turnover in a big down day - I really hope 5.5m of that is Lanstead. Otherwise we have some serious selling going on.

Wont Lanstead also be essentially forced sellers every month in accordance with the agreement? I am thinking big round figured hits on the bid side could be them doing their monthly 5.5 million?

IMO we are actually in a better position than we were at the end of May when Riddell delivered his double bombshell. We have the BOD in place with a good biotech Chairman & Dan with his huge stake & knowledge as our formal ED. Similarly we have the great news on our two papers being accepted for the ERS in early Sept, & the latest study puts to rest most of the fears raised in the botched earlier tests. So really no rationale to be under 1p going into late August pre-ERS where we should surely see some FOMO buying.

He has also not updated his Linkedin profile to reflect he is now an ED at NFX not just a consultant.

Good stuff Mars, its the link we have suspected for a long time now becoming clearer & confirmed in scientific studies. Contrary to our bombed out share price & mkt cap, it actually looks like we have the right drug at the right time.

Similarities between Long Covid & IPF being confirmed; NXP002 tests coming to positive fruition; & NXP002 presentations at ERS Congress in 3 weeks - this is the path to a deal.

Its all coming together at last, just what we needed before the ERS Congress in just over 3 weeks time.

I very much hope that's the reason for the delay in an interview Soup. It's normal practice for new management to explain themselves to shareholders shortly after appointments are made. It has been the case here at NFX after all major changes - up till now.

Hayashi, I agree with you that many of those interviews were over-egged. But there is a role for an informative explanatory interview that tells us where we are & where we hope to go in next 12 months; without over-hyping the thing (anyhow who would buy hype at NFX nowadays).

That is a staggering valuation graph:
https://www.oxilio.co.uk/investors

I appreciate its a valuation based on small placings in an illiquid private market but it just shows what a bit of effort & positive presentation can do for a company's valuation. If only....

And that becomes a practical danger when we start hawking our data around - whether at the ERS Congress or via data packages sent to pharma's. Why should they sign a big ticket deal with a biotech company they could buy outright for a tiny fraction of the likely headline figure for a deal?

It does indeed, our IP is valued at virtually zero yet our weakest patent NXP001 is the basis of another company's crazy valuation.

Which as Soup points out makes Dan's stake in Oxilio notionally now worth over 10x the value of his 37m shares in NFX.